Rapid antidepressant effect of S-ketamine in schizophrenia

Eur Neuropsychopharmacol. 2018 Aug;28(8):980-982. doi: 10.1016/j.euroneuro.2018.05.007. Epub 2018 Jul 2.


Rapid anti-suicidal and antidepressant effects of ketamine have repeatedly been confirmed in unipolar and bipolar depression. Although meaningful antidepressant efficacy of ketamine has also been shown in depressed patients with a history of psychotic symptoms, its administration in psychotic disorders has largely been neglected due to its potential to exacerbate dissociative or psychotic symptoms. Presenting a case of a young female inpatient suffering from schizophrenia with a severe post-psychotic depression, we demonstrate a robust anti-suicidal and antidepressant effect of S-ketamine infusions administered thrice weekly for 3 weeks in total. Importantly, no relevant psychotic or dissociative symptoms occurred during the whole augmentation treatment period leading to a sustained remission of depressive symptoms and suicidality. Our safe and effective experience with intravenous S-ketamine might encourage researchers and clinicians to widen its administration range beyond the diagnosis of depression to enrich the current knowledge of ketamine effects in psychotic disorders.

Keywords: Ketamine; Post-psychotic depression; Schizophrenia.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Antidepressive Agents / therapeutic use*
  • Antipsychotic Agents / therapeutic use
  • Chronic Disease
  • Depression / drug therapy*
  • Female
  • Humans
  • Ketamine / therapeutic use*
  • Schizophrenia / drug therapy*
  • Schizophrenic Psychology*
  • Suicidal Ideation


  • Antidepressive Agents
  • Antipsychotic Agents
  • Ketamine